- Home
- BIIB vs TWLO Comparison
BIIB vs TWLO Comparison
Compare BIIB & TWLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TWLO
- Stock Information
- Founded
- BIIB 1978
- TWLO 2008
- Country
- BIIB United States
- TWLO United States
- Employees
- BIIB N/A
- TWLO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TWLO Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- TWLO Technology
- Exchange
- BIIB Nasdaq
- TWLO Nasdaq
- Market Cap
- BIIB 18.7B
- TWLO 20.0B
- IPO Year
- BIIB 1991
- TWLO 2016
- Fundamental
- Price
- BIIB $132.22
- TWLO $105.64
- Analyst Decision
- BIIB Buy
- TWLO Buy
- Analyst Count
- BIIB 27
- TWLO 25
- Target Price
- BIIB $188.09
- TWLO $132.52
- AVG Volume (30 Days)
- BIIB 1.4M
- TWLO 5.9M
- Earning Date
- BIIB 10-29-2025
- TWLO 08-07-2025
- Dividend Yield
- BIIB N/A
- TWLO N/A
- EPS Growth
- BIIB 31.67
- TWLO N/A
- EPS
- BIIB 10.45
- TWLO 0.13
- Revenue
- BIIB $9,997,000,000.00
- TWLO $4,729,372,000.00
- Revenue This Year
- BIIB $2.00
- TWLO $12.99
- Revenue Next Year
- BIIB N/A
- TWLO $8.18
- P/E Ratio
- BIIB $12.64
- TWLO $832.90
- Revenue Growth
- BIIB 3.36
- TWLO 11.56
- 52 Week Low
- BIIB $110.04
- TWLO $56.85
- 52 Week High
- BIIB $206.70
- TWLO $151.95
- Technical
- Relative Strength Index (RSI)
- BIIB 46.86
- TWLO 44.87
- Support Level
- BIIB $135.22
- TWLO $102.04
- Resistance Level
- BIIB $138.50
- TWLO $106.68
- Average True Range (ATR)
- BIIB 3.37
- TWLO 3.63
- MACD
- BIIB -0.47
- TWLO 0.62
- Stochastic Oscillator
- BIIB 28.22
- TWLO 85.67
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.